Helus Pharma announced that its Phase 3 trial (APPROACH) for HLP003, a drug for major depressive disorder, has surpassed 86% enrollment, maintaining its schedule for topline data release in Q4 2026. HLP003 has FDA Breakthrough Therapy Designation due to promising Phase 2 results showing significant depression symptom reduction. The trial's progress is crucial as it tests whether these early results hold in a larger population, potentially offering a new, fast-acting treatment option for depression. Investors and patients await the Q4 2026 data to see if HLP003 can become a transformative adjunctive therapy for depression.
Cate & Chloe is participating in Walmart's Summer Deals Event from June 22 to June 28, offering its Eden 18k White Gold Plated Crystal Stud Earrings at a discounted price of $16.99, down from $77. This sale highlights the brand's focus on affordable ...
The global protein ingredients market is projected to grow from $83.14 billion in 2026 to $121.53 billion by 2031, at a CAGR of 7.9%. Growth is fueled by rising consumer demand for functional and high-protein foods, increased awareness of protein's h...
UBS Group AG has increased its stake in Bang & Olufsen A/S to 5.07% of the total share capital and voting rights as of June 23, 2026, holding 7,473,135 shares. This change follows a previous holding below 5% on June 22, 2026, marking UBS as a major s...
Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now accessible on-demand for 90 days. This event featured multiple life sciences companies presenting to investors, with opportunit...
Vaxart, a clinical-stage biotech company, has published a presentation urging shareholders to vote for all six of its director nominees at the upcoming Annual Meeting. The company highlights its progress in developing oral vaccines for COVID-19, noro...
